Japanese (NIKKEI) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Japanese Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 21 Jul 2026	JP¥68.6t	JP¥39.3t	JP¥2.8t	15.7x	24.9x	1.7x
Thu, 18 Jun 2026	JP¥67.4t	JP¥39.3t	JP¥3.1t	15x	21.7x	1.7x
Sat, 16 May 2026	JP¥69.9t	JP¥39.1t	JP¥3.1t	15x	22.7x	1.8x
Mon, 13 Apr 2026	JP¥74.9t	JP¥38.8t	JP¥3.1t	15.6x	24.4x	1.9x
Wed, 11 Mar 2026	JP¥74.9t	JP¥38.9t	JP¥3.1t	15.7x	24.4x	1.9x
Fri, 06 Feb 2026	JP¥74.2t	JP¥38.7t	JP¥3.1t	16x	23.7x	1.9x
Sun, 04 Jan 2026	JP¥70.3t	JP¥38.4t	JP¥2.7t	16.5x	25.6x	1.8x
Tue, 02 Dec 2025	JP¥70.0t	JP¥38.5t	JP¥2.8t	16.2x	25.4x	1.8x
Thu, 30 Oct 2025	JP¥65.4t	JP¥38.2t	JP¥2.7t	15.3x	24.5x	1.7x
Sat, 27 Sep 2025	JP¥63.5t	JP¥38.2t	JP¥2.7t	15.9x	23.7x	1.7x
Mon, 25 Aug 2025	JP¥64.7t	JP¥38.2t	JP¥2.7t	15.8x	24.1x	1.7x
Wed, 23 Jul 2025	JP¥61.0t	JP¥38.1t	JP¥2.6t	14.8x	23.2x	1.6x
Fri, 20 Jun 2025	JP¥62.0t	JP¥38.1t	JP¥2.6t	14.4x	23.5x	1.6x
Sun, 18 May 2025	JP¥61.8t	JP¥37.9t	JP¥2.6t	14x	23.4x	1.6x
Tue, 15 Apr 2025	JP¥58.1t	JP¥37.5t	JP¥2.4t	14x	24.2x	1.5x
Thu, 13 Mar 2025	JP¥62.8t	JP¥37.5t	JP¥2.4t	15.4x	26.3x	1.7x
Sat, 08 Feb 2025	JP¥64.0t	JP¥37.1t	JP¥2.1t	15.4x	29.9x	1.7x
Mon, 06 Jan 2025	JP¥67.2t	JP¥36.7t	JP¥2.2t	16.6x	30x	1.8x
Wed, 04 Dec 2024	JP¥69.1t	JP¥36.7t	JP¥2.2t	16x	30.8x	1.9x
Fri, 01 Nov 2024	JP¥71.7t	JP¥36.2t	JP¥2.1t	17.4x	34.9x	2x
Sun, 29 Sep 2024	JP¥70.8t	JP¥36.0t	JP¥2.0t	17.6x	35.7x	2x
Tue, 27 Aug 2024	JP¥72.8t	JP¥36.0t	JP¥2.0t	17.5x	36.7x	2x
Thu, 25 Jul 2024	JP¥69.7t	JP¥35.1t	JP¥1.8t	18.2x	37.8x	2x
Sat, 22 Jun 2024	JP¥64.7t	JP¥35.3t	JP¥1.9t	17.8x	34.6x	1.8x
Mon, 20 May 2024	JP¥65.6t	JP¥35.3t	JP¥1.9t	17.4x	35.1x	1.9x
Wed, 17 Apr 2024	JP¥62.5t	JP¥34.7t	JP¥1.9t	17.5x	32.1x	1.8x
Fri, 15 Mar 2024	JP¥67.3t	JP¥35.1t	JP¥2.0t	18.4x	34.3x	1.9x
Sun, 11 Feb 2024	JP¥65.5t	JP¥35.1t	JP¥2.1t	18.5x	31.9x	1.9x
Tue, 09 Jan 2024	JP¥63.8t	JP¥35.0t	JP¥2.2t	18.7x	29.6x	1.8x
Thu, 07 Dec 2023	JP¥64.5t	JP¥35.0t	JP¥2.2t	17.7x	30x	1.8x
Sat, 04 Nov 2023	JP¥61.4t	JP¥34.7t	JP¥2.2t	17.2x	28.1x	1.8x
Mon, 02 Oct 2023	JP¥63.2t	JP¥34.5t	JP¥2.3t	17.7x	27.8x	1.8x
Wed, 30 Aug 2023	JP¥64.2t	JP¥34.5t	JP¥2.3t	18.1x	28.4x	1.9x
Fri, 28 Jul 2023	JP¥63.9t	JP¥34.0t	JP¥2.3t	18.4x	27.5x	1.9x

Current Industry PE

Investors are pessimistic on the Japanese Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 24.9x which is lower than its 3-year average PE of 28.4x.

The industry is trading close to its 3-year average PS ratio of 1.8x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have grown 6.0% per year over the last three years.
Revenues for these companies have grown 5.0% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare sector?


JP Market	-3.22%
Healthcare	0.76%
Healthcare Services	2.57%
Pharma	1.29%
Medical Equipment	-0.42%
Healthtech	-1.48%
Life Sciences	-2.16%
Biotech	-3.61%

Industry PE

Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 178x.

Analysts are expecting annual earnings growth of 5.3%, which is higher than its past year's earnings decline of 16.4% per year.

Forecasted Growth

Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 39% over the next 5 years.
This is better than its past earnings growth rate of 11% per year.

In contrast, the Healthcare Services industry is expected to see its earnings grow by 3.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
4502 Takeda Pharmaceutical	JP¥5.48k	2.9% +JP¥241.7b	28.8%	PS1.9x
4568 Daiichi Sankyo Company	JP¥2.79k	4.2% +JP¥199.4b	-20.1%	PE19.2x
4519 Chugai Pharmaceutical	JP¥7.33k	1.2% +JP¥138.2b	8.0%	PE26.7x
4543 Terumo	JP¥2.27k	1.5% +JP¥50.9b	-3.9%	PE24.6x
6869 Sysmex	JP¥1.63k	4.3% +JP¥40.6b	-31.6%	PE27.8x

Olympus Corporation Announces Management Changes, Effective August 1, 2026

Olympus Corporation announced that the Board of Directors resolved to change the Executive Officer and Chief Quality Officer, effective August 1, 2026. Reason for change of Executive Officer: Boris Shkolnik led the establishment of the global quality function and system as Olympus, strengthened its position as a global medtech company. During this transformation, he enhanced engagement with the FDA, advanced the Quality Management System to improve global standardization and audit readiness, designed and established global Quality and Regulatory Affairs functions and drove the adoption of a patient safety and quality culture across the organization. His leadership helped establish a stronger foundation for quality and regulatory compliance. To support strategic growth investments, remain committed to proactive and constructive engagement with global regulators, including the US FDA, with a clear focus on achieving a sustainable, fully compliant end state that underpins long-term value creation. Brian Barry will succeed him and lead the next phase of the company's quality transformation; he brings more than 40 years of leadership experience across global Quality, Regulatory Affairs, Medical Safety, and Clinical Affairs. He has demonstrated expertise in strategic planning, organizational development, regulatory compliance, lean transformation, and regulatory agency engagement. With a strong track record in leading complex acquisitions and divestitures, improving quality system performance, and successfully resolving regulatory challenges, Brian will play a key role in further strengthening quality system, advancing patient safety and driving a quality culture. Names and job titles of newly appointed and retiring executive officers: Newly appointed executive officer: Brian Barry: New job titles after August 1, 2026: Executive Officer and Chief Quality Officer. Boris Shkolnik: Current job titles: Executive Officer and Chief Quality Officer. Brian Barry: Date of Birth: August 22, 1959 July 1981: Joined United States Surgical Corporation. September 1988: Quality Assurance Manager, Disposable Products, Corometrics Medical Systems Inc. (acquired by Marquette Electronics). December 1989: Sr. Director, Regulatory Affairs & Quality Assurance, Corometrics Medical Systems Inc. (acquired by Marquette Electronics). July 1994: Vice President, Regulatory Affairs & Quality Assurance, Bard Access Systems Inc. January 1997: Vice President, Corporate Regulatory Affairs, C. R. Bard Inc. December 2000: Vice President, Regulatory, Clinical & Quality Affairs, Medtronic Xomed Inc. September 2003 Vice President, Corporate Regulatory Affairs & Clinical Affairs, C. R. Bard Inc. June 2007: Vice President, Quality, Regulatory, Clinical & Medical Affairs, Medtronic Sofamor Danek USA Inc. September 2013: Vice President, Corporate Regulatory Affair, Covidien plc (acquired by Medtronic plc) February 2015: Group Vice President, Quality, Regulatory Affairs, Medical Safety & Scientific Communications, Minimally Invasive Therapies Group, Medtronic plc February 2021: Vice President, Global Regulatory Shared Services, Medtronic Corporate Regulatory Affairs, Medtronic plc January 2023: Vice President, Medtronic Clinical & Regulatory Solutions, Medtronic plc (present) August 2026: Join Olympus Corporation of the Americas (plan) Executive Officer, Chief Quality Officer, Olympus Corporation (plan) New management team from August 1, 2026: The executive officers are stated by the alphabetical order of last name excluding the representative officer. Bob White: Director, Representative Executive Officer, President and Chief Executive Officer; Brian Barry: Executive Officer, Chief Quality Officer; Simone Berger: Executive Officer, Chief Human Resources Officer; Keith Boettiger: Executive Officer, Gastrointestinal Solutions Division Head; John de Csepel: Executive Officer, Chief Medical Officer; Gabriela Kaynor: Executive Officer, Chief Strategy Officer; Seiji Kuramoto: Executive Officer, Surgical and Interventional Solutions Division Head; Syed Naveed: Executive Officer, Chief Technology Officer; Michael Parenti: Executive Officer, Chief Financial Officer; David Shan: Executive Officer, Chief Manufacturing and Supply Officer; Neil Boyden Tanner: Executive Officer, Global General Counsel.

Japanese (NIKKEI) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Shionogi & Co., Ltd. Application For Expanded Pediatric Indication For Cefiderocol Accepted By U.S. FDA

Mani, Inc. Revises Upward Consolidated Earnings Guidance for the Full Year Ending August 31, 2026

Canada Recommends Public Coverage for Eisai Alzheimer’s Drug LEQEMBI in Major Milestone

Olympus Corporation Announces Management Changes, Effective August 1, 2026

Takeda Announces New Data from Two Pivotal Phase 3 Studies of Zasocitinib in Adults with Moderate-To-Severe Plaque Psoriasis

4519: Stock Compensation Plan And AI Aging Collaboration Will Drive Long-Term Upside

MediPal Holdings Finalizes Paltac Acquisition and Lifts Profit and Dividend Forecasts

4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential

New major risk - Shareholder dilution

We Like The Quality Of Terumo's (TSE:4543) Earnings

New minor risk - Earnings quality

Full year 2026 earnings: EPS and revenues exceed analyst expectations

Now 21% overvalued after recent price rise

Now 23% overvalued after recent price rise

M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026

Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026